Binimetinib: Preliminary Phase II data

Preliminary data from 40 BRAF and MEK inhibitor-naive patients with locally advanced or metastatic BRAF V600 mutation-positive melanoma in Group A of Part 1 of the 2-part, open-label, international Phase II LOGIC2 trial showed that once-daily 450 mg oral encorafenib plus twice-daily 45 mg oral binimetinib led to an ORR of 68%, including 1 complete response and 26 partial responses, plus 11 cases of stable disease. The DCR was 95% and the 6-month PFS rate was 79%. In Part 1, patients are separated into 3 groups based on previous exposure to BRAF and MEK inhibitors and are treated with encorafenib and binimetinib until disease progression. Based on the results of molecular profiling at that time, each patient is assigned to 1 of 4 arms containing a triple combination of binimetinib, encorafenib and a third targeted therapy. ...